You are here

Epidiolex

3 Biotechs With Huge FDA Decisions in June

3 Biotechs With Huge FDA Decisions in June

Motley Fool

Array Biopharma

Flag link:

This Cannabis-Based Drug Is On the Verge of Making History

This Cannabis-Based Drug Is On the Verge of Making History

Motley Fool

Dravet syndrome

Lennox-Gastaut Syndrome

Flag link:

A look at The First Company Likely to Market an FDA Approved Cannabinoid in the US

A look at The First Company Likely to Market an FDA Approved Cannabinoid in the US

CP Wire

Flag link:

FDA Panel Votes To Approve Marijuana-Based Drug For Epilepsy

FDA Panel Votes To Approve Marijuana-Based Drug For Epilepsy

Forbes

advisory panels

Flag link:

GW Pharma riding high as cannabinoid Epidiolex nears first U.S. approval

GW Pharma riding high as cannabinoid Epidiolex nears first U.S. approval

Fierce Biotech

Flag link:

3 Biotechs That Could Get Big Boosts in April

3 Biotechs That Could Get Big Boosts in April

Motley Fool

Neurocrine Biosciences

Flag link:

3 Blockbuster Drug Launches to Watch In 2018

3 Blockbuster Drug Launches to Watch In 2018

Motley Fool

Gilead Sciences

Flag link:

GW Pharma shares dented after cannabinoid drug fails a PhIIa study on focal seizures

GW Pharma shares dented after cannabinoid drug fails a PhIIa study on focal seizures

Endpoints

clinical trials

Flag link:

A Tiny Biotech Just Dealt a Big Blow to Marijuana's Use in Epilepsy

A Tiny Biotech Just Dealt a Big Blow to Marijuana's Use in Epilepsy

Motley Fool

Flag link:

Zogenix: Could This Be The Greatest Threat to GW Pharmaceuticals?

Zogenix: Could This Be The Greatest Threat to GW Pharmaceuticals?

Motley Fool

Dravet syndrome

Flag link:

GW Pharmaceuticals’ Cannabis Drug Show Promise in Late-Stage Clinical Trial of Epilepsy

GW Pharmaceuticals’ Cannabis Drug Show Promise in Late-Stage Clinical Trial of Epilepsy

Xtalks

clinical trials

Dravet syndrome

Flag link:

3 Reasons GW Pharmaceuticals Stock Could Rise

3 Reasons GW Pharmaceuticals Stock Could Rise

Motley Fool

Flag link:

3 for 3 in PhIII: GW Pharma racing to the FDA after bagging another late-stage epilepsy success

3 for 3 in PhIII: GW Pharma racing to the FDA after bagging another late-stage epilepsy success

Endpoints

Flag link:

GW Pharma to raise $252 mln after cannabis drug success

GW Pharma to raise $252 mln after cannabis drug success

Yahoo/Reuters

Flag link:

5 Major Clinical Trial Results Coming Up

5 Major Clinical Trial Results Coming Up

24/7 Wall St

clinical trials

Vertex Pharmaceuticals

Puma Biotechnology

Agios Pharmaceuticals

Flag link:

GW Pharmaceuticals' Marijuana-Based Drug Hits the Mark in Pivotal-Stage Study

GW Pharmaceuticals' Marijuana-Based Drug Hits the Mark in Pivotal-Stage Study

Motley Fool

Flag link:

GW Pharma CEO jumps to the U.S., betting on epilepsy approval

GW Pharma CEO jumps to the U.S., betting on epilepsy approval

Fierce Biotech

Flag link:

Pages